| Peer-Reviewed

A Cross Sectional Study to Assess the Association of Thyroid Autoantibodies with Thyroid Malignancies in a Tertiary Care Hospital in Bangladesh

Received: 13 April 2021    Accepted: 15 June 2021    Published: 30 June 2021
Views:       Downloads:
Abstract

Thyroid cancer is the most common endocrine malignant lesion and its incidence continues to rise. The aim of this study was to assess association between thyroid antibodies and thyroid malignancies. This was a cross sectional study of 120 patients with thyroid nodules undergoing thyroidectomy with recorded preoperative thyroid antibodies [autoantibodies to thyroglobulin (TgAb) and/or thyroid peroxidase (TPOAb)] levels from 2017 to 2018 admitted at the ENT Department of Chittagong Medical College Hospital, Chittagong. Analysis was done to assess the association between preoperative thyroid antibody levels, fine needle aspiration cytology (FNAC) results, type of thyroid surgery and final histopathology. Mean age of the study population was 35.58 years (SD:±11.36). According to the final histopathological diagnosis of the 120 patients 80% were benign and other 20% were malignant. Men are more likely to suffer from thyroid malignancy than women (33.3% versus 18.9%). Multinodules are predominant group than solitary nodule (55% versus 45%). Though the prevalence of thyroid malignancies is more in solitary group than multinodules group (22.2% versus 18.2%) the difference is not statistically significant. Among the benign nodules most of them (88.5%) were nodular goiter and among the malignancies most of them were (80.3%) were papillary thyroid carcinoma. There is moderate agreement between FNA and histopathological diagnosis (kappa is .405). The patients with high TSH level in comparison to low TSH level were significantly associated with thyroid malignancy. The patients with preoperative elevated TgAb (≥ 40IU/mL) has 2.55 times of more chance to have malignant lesion than the patients who has normal TgAb level. The study revealed that elevated level of TgAb may act as an independent prediction factor for thyroid malignancy.

Published in American Journal of Biomedical and Life Sciences (Volume 9, Issue 3)
DOI 10.11648/j.ajbls.20210903.14
Page(s) 166-175
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Thyroid Nodule, Autoantibody, Malignancy

References
[1] Carling T, Udelsman R. Thyroidcancer. Ann Rev Med 2014; 65 (1): 125-137.
[2] Curado MP, Edwards B, Shinetal HR. Cancerincidence in five continents. IARC Sci Pub2007; 9: 160.
[3] Kilfoy BA, Zheng T, Holford TR. International patterns and trends in thyroid cancer incidence, 1973–2002. Canc Caus Contl 2009; 20 (5): 525–531.
[4] http://seer.cancer.gov/ statfacts/html/thyro.html
[5] Jemal A, Siegel R, Xu J, Ward E. Cancerstatistics, 2010. CA: A Canc J for Clini 2010; 60 (5): 277–300.
[6] Aschebrook KB, Kaplan KL, Chiu BC, Angelos P, Grogan RH. The acceleration in papillary thyroid cancer incidence rates is similar among racial and ethnic groups in the United States. Annals of Surg Onco 2013; 20 (8): 2746-53.
[7] Weigle DS, Hooton TM, Toivola B et al. Frequency of thyroid disease among Southeast Asian primary care patients. J clin Pharm Ther 1996; 21: 29-35.
[8] Alam MN, Haq SA, Ansari MAJ et al. Spectrum of Thyroid Disorders in IPGMR, Dhaka. Bangladesh J Medicine 1995; 6: 53-58.
[9] Al Robbani AM. Study of Thyroid Carcinoma in Solitary thyroid Nodule. Dinajpur Med Col J 2013Jan; 6 (1): 58-63.
[10] Mazzaferri EL. Thyroid cancer in thyroid nodules: finding a needle in the hay stack. The American J of Medi 1992; 93 (4): 359–362.
[11] Boelaert K. The association between serum TSH concentration and thyroid cancer: Endocrine related cancer 2009; 16: 1065-1072.
[12] Hossain MA, Sarkar MZ, Datta UK, Karim MA, et al. Frequency of malignancy in solitary thyroid nodule and multi-nodular goiter. Bangladesh J Otorhinolaryngology 2014; 20 (2): 55-65.
[13] Shi L, Li Y, Guan H. Usefulness of serum thyrotropin for risk prediction of differentiated thyroid cancers does not apply to microcarcinomas: results of 1870 Chinese patients with thyroid nodules. Endocrine J 2012; 59 (11): 973-980.
[14] McLeod DSA, Watters KF, Carpenter AD, Ladenson PW, et al. Thyrotropin and thyroid cancer diagnosis: a systematic review and dose response meta-analysis. The J of clini Endocrino and metabolism 2012; 97 (8): 2682-2692.
[15] Fiore E, Vitti P. Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J Clini Endocrino and Metabolism 2012; 97 (4): 1134-1145.
[16] Scheffler P, Forest VI, Leboeuf R, Florea AV, Tamilia M, Sands NB, et al. Serum thyroglobulin improves the sensitivity of the McGill thyroid nodule score for well-differentiated thyroid cancer. Thyroid. 2014; 24 (5): 852-7.
[17] Sands NB, Karls S, Rivera J, Tamilia M, Hier MP, Black MJ, Gologan O, Payne RJ. Preoperative serum thyroglobulin as an adjunct to fine-needle aspiration in predicting well-differentiated thyroid cancer. J Otolaryngol Head Neck Surg 2010; 39: 669–73.
[18] Hocevar M, Auersperg M. Role of serum thyroglobulin in the pre-operative evaluation of follicular thyroid tumours. Eur J Surg Oncol 1998; 24:553–7.
[19] Lee EK, Chung KW, Min HS, Kim TS, Kim TH, Ryu JS, Jung YS, Kim SK, Lee YJ. Preoperative serum thyroglobulin as a useful predictive marker to differentiate follicular thyroid cancer from benign nodules in indeterminate nodules. J Korean Med Sci. 2012; 27: 1014–8.
[20] Spencer CA. Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab 2011; 96 (12): 3615–27.
[21] Kim ES, Lim DJ, Baek KH, Lee JM, Kim MK, Kwon HS, et al. Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules. Thyroid 2010; 20 (8): 885–91.
[22] Hasanat MA, Rumi MAK, Alam MN, Hasan KN, et al. Status of antithyroid antibodies in Bangladesh: Postgrad Med J 2000; 76: 345-349.
[23] Polyzos SA, Kita M, Avramids. Thyroid nodules- Stepwise diagnosis and management. Homones 2007; 6 (2): 101-119.
[24] Welker MJ. Thyroid nodules. American family/Physician 2003; 67 (3): 559-66.
[25] Yassa L, Cibas ES, Benson CB, Frates MC, Doubilt PM et al. Longterm assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer 2007; 11: 508-516.
[26] Gleeson MC, Browning G, Burton MJ, Clarke R, Hibbert JN, Jones NC, et al. Scott-Brown’s Otorhinolaryngology, Head and neck Surgery. 7th ed. London, Edward Arnold publishers Ltd; 2008. P. 2672-73.
[27] Gleeson MC, Browning G, Burton MJ, Clarke R, Hibbert JN, Jones NC, et al. Scott-Brown’s Otorhinolaryngology, Head and neck Surgery. 7th ed. London, Edward Arnold publishers Ltd; 2008. P. 343.
[28] https://en.m.wikipedia.org>wiki>Anti-thyroid autoantibodies
[29] Gleeson MC, Browning G, Burton MJ, Clarke R, Hibbert JN, Jones NC, et al. Scott-Brown’s Otorhinolaryngology, Head and neck Surgery. 7th ed. London, Edward Arnold publishers Ltd; 2008. P. 356.
[30] Hosseini S, Payne RJ, Zawawi F, Mlynarek A, Hier MP, et al. Can preoperative thyroglobulin antibody levels be used as a marker for well differentiated thyroid cancer? J of Otolaryngology - Head and Neck Surgery, 2016; 45: 31.
[31] Qin J, Zhenqian Y, Haixia G, Liangfeng S, Yongping L, et al. High thyroglobulin antibody levels increase the risk of differentiated thyroid carcinoma. Disease Markers. 2015; Article ID 648670.
[32] Wong SL, Grodski S, Yeung MJ, Serpell JW. Anti-thyroid antibodies as a predictor of thyroid cancer. ANZ J Surg. 2015; 85 (11): 849-53.
[33] Lee SH, Baek JS, Lee JY, Lim JA, Cho SY, et al. Predictive factors of malignancy in thyroid nodules with a cytological diagnosis of follicular neoplasm. Endocr Pathol. 2013; 24 (4): 177-83.
[34] Jaheen H, Sakr M. Predictors of malignancy in patients with solitary and multiple thyroid nodules. J of Surg. 2016; 12 (3): 105-110.
[35] Grani G, Calvanese A, Carbotta G, D'Alessandri M, Nesca A, Bianchini M, et al. Thyroid autoimmunity and risk of malignancy in thyroid nodules submitted to fine-needle aspiration cytology. Head Neck. 2013; 24 (5): 852-7.
[36] Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. Sereum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clini Endocri Metabolism, 2006; 91: 4295-4301.
[37] Rago T, DiCoscio G, Ugolini C, Scutari M, Basolo F, et al. Clinical features of thyroid autoimmunity are associated with thyroiditis on histology and are not predictive of malignancy in 570 patients in indeterminate nodules on cytology who had a thyroidectomy. Clin Endocrinol, 2007; 67: 363-369.
[38] Fiore ERT, Provenzale MA, Scutari M, Ugolini C, Basolo F, et al. Lower level of TSH are associated to a lower risk of papillary thyroid cancer in patients with thyroid nodular diseases: thyroid autonomy may play a protective role. Endocr Relat Cancer. 2009; 16: 1251-1260.
[39] Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Archives of Surgery, 1995; 70 (2): 291–297.
[40] Azizi G, Keller JM, Lewisetal M. Association of Hashimoto’s thyroiditis with thyroid cancer. Endocrine-Related Cancer, 2014; 21 (6): 845–852.
[41] Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Henry JF, et al. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003; 13: 1–126.
[42] Spencer C, Fatemi S 2013 Thyroglobulin antibody (TgAb) methods—strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab 2013. DOI: 10.1016.
[43] Chiovato L, Latrofa F, Breverman LE, Pacini F, Capezzone M, et al. Disapperance of humoreal thyroid autoimmunity after complete removal of thyroid antigen. Ann Inter Med, 2003; 139: 346-351.
[44] Chung JK, Park YJ, Kim TY, So Y, Kim SK, et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clinical endrocrinology 2002; 57 (2): 215-221.
[45] Kim WG, Yoon JH, Kim WB, Kim TY, Kim ET, et al. Change of serum anti thyroglobulin antibody levels is useful prediction of clinical recurrence in thyroglobulin- negative patients with differentiated thyroid carcinoma. Journal Clinical Metabolism 2008; 93: 4683-4689.
[46] Arun K, Nayak SK, Gowda S. Observational study on association between serum thyroid stimulating hormone and thyroid malignancy. Int Surg J 2017; 4: 2002-6.
[47] Ichikawa Y, Saito E, Abe Y, Homma M, Muraki T, Ito K. Presence of TSH receptor in thyroid neoplasms. J Clin Endocrinol Metab 1976; 42 (2): 395-8.
[48] Frates MC, Benson CB, Doubilet PM. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J of Clini Endocri and Metabolism 2006; 91 (9): 3411–3417.
[49] Rago T, Fiore E, Scutarietal M. Male sex, single nodularity, and young age are associated with the risk of finding a papillary thyroid cancer on fine-needle aspiration cytology in a large series of patients with nodular thyroid disease. European JofEndocrino 2010; 162 (4): 763–770.
[50] Raparia K, Min SK, Mody DR, Anton R, Amrikachi M. Clinical outcomes for “suspicious” category in thyroid fineneedle aspiration biopsy: patient’s sex and nodule size are possible predictors of malignancy. Archives of Pathology and Laboratory Medicine 2009; 133 (5): 787–790.
[51] Lubitz CC, Faquin WC, Yang J. Clinical and cytological features predictive of malignancy in thyroid follicular neoplasms. Thyroid 2010; 20 (1): 25–31.
[52] Verburg FA, Luster M, Cupini C, Chiovato L, Duntas L, Elisei R, et al. Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. Thyroid 2013; 23 (10): 1211–25.
[53] Hajmanoochehri F, Rabiee E. FNAC accuracy in diagnosis of thyroid neoplasms considering all diagnostic categories of the Bethesda reporting system: A single-institute experience. J Cytol 2015 Oct-Dec; 32 (4): 238–243.
[54] Bagga PK, Mahajan NC. Fine needle aspiration cytology of thyroid swellings: How useful and accurate is it? Indian J Cancer 2010; 47: 437–42.
[55] Handa U, Garg S, Mohan H, Nagarkar N. Role of fine needle aspiration cytology in diagnosis and management of thyroid lesions: A study on 434 patients. Journal Cytol 2008; 25: 13–7.
[56] Wong LQ, Baloch ZW. Analysis of the Bethesda system for reporting thyroid cytopathology and similar precursor thyroid cytopathology reporting schemes. Adv Anat Pathol 2012; 19: 313–9.
[57] Yang J, Schnadig V, Logrono R, Wasserman PG. Fine-needle aspiration of thyroid nodules: A study of 4703 patients with histologic and clinical correlations. Cancer 2007; 111: 306–15.
Cite This Article
  • APA Style

    Mitan Chakma, Milton Barua, Kyaw Khin U, Mahmud Ullah Faruquee, Sayed Muhammad Alauddin Sharif, et al. (2021). A Cross Sectional Study to Assess the Association of Thyroid Autoantibodies with Thyroid Malignancies in a Tertiary Care Hospital in Bangladesh. American Journal of Biomedical and Life Sciences, 9(3), 166-175. https://doi.org/10.11648/j.ajbls.20210903.14

    Copy | Download

    ACS Style

    Mitan Chakma; Milton Barua; Kyaw Khin U; Mahmud Ullah Faruquee; Sayed Muhammad Alauddin Sharif, et al. A Cross Sectional Study to Assess the Association of Thyroid Autoantibodies with Thyroid Malignancies in a Tertiary Care Hospital in Bangladesh. Am. J. Biomed. Life Sci. 2021, 9(3), 166-175. doi: 10.11648/j.ajbls.20210903.14

    Copy | Download

    AMA Style

    Mitan Chakma, Milton Barua, Kyaw Khin U, Mahmud Ullah Faruquee, Sayed Muhammad Alauddin Sharif, et al. A Cross Sectional Study to Assess the Association of Thyroid Autoantibodies with Thyroid Malignancies in a Tertiary Care Hospital in Bangladesh. Am J Biomed Life Sci. 2021;9(3):166-175. doi: 10.11648/j.ajbls.20210903.14

    Copy | Download

  • @article{10.11648/j.ajbls.20210903.14,
      author = {Mitan Chakma and Milton Barua and Kyaw Khin U and Mahmud Ullah Faruquee and Sayed Muhammad Alauddin Sharif and Shahin Ibn Rahman and Afjal Hossain and Amanat Ullah},
      title = {A Cross Sectional Study to Assess the Association of Thyroid Autoantibodies with Thyroid Malignancies in a Tertiary Care Hospital in Bangladesh},
      journal = {American Journal of Biomedical and Life Sciences},
      volume = {9},
      number = {3},
      pages = {166-175},
      doi = {10.11648/j.ajbls.20210903.14},
      url = {https://doi.org/10.11648/j.ajbls.20210903.14},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbls.20210903.14},
      abstract = {Thyroid cancer is the most common endocrine malignant lesion and its incidence continues to rise. The aim of this study was to assess association between thyroid antibodies and thyroid malignancies. This was a cross sectional study of 120 patients with thyroid nodules undergoing thyroidectomy with recorded preoperative thyroid antibodies [autoantibodies to thyroglobulin (TgAb) and/or thyroid peroxidase (TPOAb)] levels from 2017 to 2018 admitted at the ENT Department of Chittagong Medical College Hospital, Chittagong. Analysis was done to assess the association between preoperative thyroid antibody levels, fine needle aspiration cytology (FNAC) results, type of thyroid surgery and final histopathology. Mean age of the study population was 35.58 years (SD:±11.36). According to the final histopathological diagnosis of the 120 patients 80% were benign and other 20% were malignant. Men are more likely to suffer from thyroid malignancy than women (33.3% versus 18.9%). Multinodules are predominant group than solitary nodule (55% versus 45%). Though the prevalence of thyroid malignancies is more in solitary group than multinodules group (22.2% versus 18.2%) the difference is not statistically significant. Among the benign nodules most of them (88.5%) were nodular goiter and among the malignancies most of them were (80.3%) were papillary thyroid carcinoma. There is moderate agreement between FNA and histopathological diagnosis (kappa is .405). The patients with high TSH level in comparison to low TSH level were significantly associated with thyroid malignancy. The patients with preoperative elevated TgAb (≥ 40IU/mL) has 2.55 times of more chance to have malignant lesion than the patients who has normal TgAb level. The study revealed that elevated level of TgAb may act as an independent prediction factor for thyroid malignancy.},
     year = {2021}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - A Cross Sectional Study to Assess the Association of Thyroid Autoantibodies with Thyroid Malignancies in a Tertiary Care Hospital in Bangladesh
    AU  - Mitan Chakma
    AU  - Milton Barua
    AU  - Kyaw Khin U
    AU  - Mahmud Ullah Faruquee
    AU  - Sayed Muhammad Alauddin Sharif
    AU  - Shahin Ibn Rahman
    AU  - Afjal Hossain
    AU  - Amanat Ullah
    Y1  - 2021/06/30
    PY  - 2021
    N1  - https://doi.org/10.11648/j.ajbls.20210903.14
    DO  - 10.11648/j.ajbls.20210903.14
    T2  - American Journal of Biomedical and Life Sciences
    JF  - American Journal of Biomedical and Life Sciences
    JO  - American Journal of Biomedical and Life Sciences
    SP  - 166
    EP  - 175
    PB  - Science Publishing Group
    SN  - 2330-880X
    UR  - https://doi.org/10.11648/j.ajbls.20210903.14
    AB  - Thyroid cancer is the most common endocrine malignant lesion and its incidence continues to rise. The aim of this study was to assess association between thyroid antibodies and thyroid malignancies. This was a cross sectional study of 120 patients with thyroid nodules undergoing thyroidectomy with recorded preoperative thyroid antibodies [autoantibodies to thyroglobulin (TgAb) and/or thyroid peroxidase (TPOAb)] levels from 2017 to 2018 admitted at the ENT Department of Chittagong Medical College Hospital, Chittagong. Analysis was done to assess the association between preoperative thyroid antibody levels, fine needle aspiration cytology (FNAC) results, type of thyroid surgery and final histopathology. Mean age of the study population was 35.58 years (SD:±11.36). According to the final histopathological diagnosis of the 120 patients 80% were benign and other 20% were malignant. Men are more likely to suffer from thyroid malignancy than women (33.3% versus 18.9%). Multinodules are predominant group than solitary nodule (55% versus 45%). Though the prevalence of thyroid malignancies is more in solitary group than multinodules group (22.2% versus 18.2%) the difference is not statistically significant. Among the benign nodules most of them (88.5%) were nodular goiter and among the malignancies most of them were (80.3%) were papillary thyroid carcinoma. There is moderate agreement between FNA and histopathological diagnosis (kappa is .405). The patients with high TSH level in comparison to low TSH level were significantly associated with thyroid malignancy. The patients with preoperative elevated TgAb (≥ 40IU/mL) has 2.55 times of more chance to have malignant lesion than the patients who has normal TgAb level. The study revealed that elevated level of TgAb may act as an independent prediction factor for thyroid malignancy.
    VL  - 9
    IS  - 3
    ER  - 

    Copy | Download

Author Information
  • Department of Otolaryngology, Chittagong Medical College Hospital, Chittagong, Bangladesh

  • Department of Medicine, Chittagong General Hospital, Chittagong, Bangladesh

  • Department of Otolaryngology, Chittagong Medical College Hospital, Chittagong, Bangladesh

  • Department of Otolaryngology, Chittagong Medical College Hospital, Chittagong, Bangladesh

  • Department of Otolaryngology, Chittagong Medical College Hospital, Chittagong, Bangladesh

  • epartment of Endocrinology, Dhaka National Medical College Hospital, Dhaka, Bangladesh

  • Department of Endocrinology, US Bangla Medical College, Narayanganj, Bangladesh

  • Acute Medicine, Medway Maritime Hospital, Kent, UK

  • Sections